Пептична виразка шлунка та дванадцятипалої кишки адаптована клінічна настанова, заснована на доказах

96.Dore MP, Sepulveda AR, Osato MS, Realdi G, Graham DY. Helicobacter pylori in sheep milk. Lancet 1999;354 (9173):132

97.Dore MP, Sepulveda AR, El-Zimaity H et al. Isolation of Helicobacter pylori from sheep-implications for transmission to humans. Am J Gastroenterol 2001;96 (5):1396-1401

98.Rocha GA, Rocha AM, Silva LD et al. Transmission of Helicobacter pylori infection in families of preschool-aged children from Minas Gerais, Brazil. Trop Med Int Health 2003;8 (11):987-991

99.Rothenbacher D, Winkler M, Gonser T, Adler G, Brenner H. Role of infected parents in transmission of helicobacter pylori to their children. Pediatr Infect Dis J 2002;21 (7):674-679

100. Kivi M, Johansson AL, Reilly M, Tindberg Y. Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect 2005;133 (4):645-652

101. Tindberg Y, Bengtsson C, Granath F et al. Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology 2001;121 (2):310-316

102. Han SR, Zschausch HC, Meyer HG et al. Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol 2000;38 (10):3646-3651

103. Kivi M, Tindberg Y, Sorberg M et al. Concordance of Helicobacter pylori strains within families. J Clin Microbiol 2003;41 (12):5604-5608

104. Mendall MA, Goggin PM, Molineaux N et al. Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet 1992;339 (8798):896-897

105. Goodman KJ, Correa P. Transmission of Helicobacter pylori among siblings. Lancet 2000;355 (9201):358-362

106. Rowland M, Daly L, Vaughan M et al. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006;130 (1):65-72; quiz 211

107. Goodman KJ, Correa P, Tengana Aux HJ et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996;144 (3):290-299

108. Glynn MK, Friedman CR, Gold BD et al. Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis 2002;35 (9):1059-1065

109. Aguemon BD, Struelens MJ, Massougbodji A, Ouendo EM. Prevalence and risk-factors for Helicobacter pylori infection in urban and rural Beninese populations. Clin Microbiol Infect 2005;11 (8):611-617

110. Klein PD, Graham DY, Gaillour A, Opekun AR, Smith EO. W ater source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet 1991;337 (8756):1503-1506

111. Hulten K, Han SW, Enroth H et al. Helicobacter pylori in the drinking water in Peru. Gastroenterology 1996;110 (4):1031-1035

112. Lu Y, Redlinger TE, Avitia R, Galindo A, Goodman K. Isolation and genotyping of Helicobacter pylori from untreated municipal wastewater. Appl Environ Microbiol 2002;68 (3):1436-1439

113. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388 (6642):539-547

114. Wheeldon TU, Hoang TT, Phung DC et al. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 2005;21 (8):1047-1053

115. Feydt-Schmidt A, Kindermann A, Konstantopoulos N et al. Reinfection rate in children after successful Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2002;14 (10):1119-1123

116. Svennerholm AM, Lundgren A. Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol 2007;50 (2):146-156

117. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007;133 (1):288-308

118. Kivi M, Tindberg Y. Helicobacter pylori occurrence and transmission: a family affair? Scand J Infect Dis 2006;38 (6-7):407-417

119. Kuepper-Nybelen J, Thefeld W , Rothenbacher D, Brenner H. Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults. Aliment Pharmacol Ther 2005;21 (1):57-64

120. Metzger W G, Mansouri E, Kronawitter M et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004;22 (17-18):2273-2277

121. Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004;53 (9):1235-1243

122. Losonsky GA, Kotloff KL, W alker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HW C) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine 2003;21 (5-6):562-565

123. Banerjee S, Medina-Fatimi A, Nichols R et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002;51 (5):634-640

124. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001;20 (5-6):879-885

125. Kotloff KL, Sztein MB, Wasserman SS et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001;69 (6):3581-3590

126. Bumann D, Metzger W G, Mansouri E et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001;20 (5-6):845-852

127. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella terica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000;68 (4):2135-2141

128. Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 1999;4 (4):272-280

129. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116 (4):804-812

130. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999;18 (5-6):449-459

153. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Bmj 1991;302 (6788):1302-1305

154. Forman D, Sitas F, Newell DG et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990;46 (4):608-611

155. Stolte M, Eidt S. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori? J Clin Pathol 1989;42 (12):1269-1271

156. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Jama 1994;272 (1):65-69

157. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994;89 (8):1137-1139

158. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120 (12):977-981

159. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114 (6):1169-1179

160. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13 (7):851-856

161. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94 (9):2373-2379

162. Xue FB, Xu YY, Wan Y et al. Association of H. pylori infection with gastric carcinoma: a Meta analysis. W orld J Gastroenterol 2001;7 (6):801-804

163. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125 (6):1636-1644

164. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49 (3):347-353

165. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004;159 (3):252-258

166. Harsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330 (18):1267-1271

167. Lehours P, Dupouy S, Bergey B et al. Identification of a genetic marker of Helicobacter pylori strains involved in gastric extranodal marginal zone B cell lymphoma of the MALT-type. Gut 2004;53 (7):931-937

168. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001;14 (1):59-97

169. Morgner A, Lehn N, Andersen LP et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000;118 (5):821-828

170. Noone PA, Waclawski ER, W att AD. Are endoscopy nurses at risk of infection with Helicobacter pylori from their work? Occup Med (Lond) 2006;56 (2):122-128

171. Mastromarino P, Conti C, Donato K et al. Does hospital work constitute a risk factor for Helicobacter pylori infection? J Hosp Infect 2005;60 (3):261-268

172. Matsuda R, Morizane T. Helicobacter pylori infection in dental professionals: a 6-year prospective study. Helicobacter 2005;10 (4):307-311

173. Kim N, Lim SH, Lee KH et al. Seroconversion of Helicobacter pylori in Korean male employees. Scand J Gastroenterol 2005;40 (9):1021-1027

174. Braden B, Duan LP, Caspary WF, Lembcke B. Endoscopy is not a risk factor for Helicobacter pylori infection--but medical practice is. Gastrointest Endosc 1997;46 (4):305-310

II. Diagnostik, Typisierung, Resistenzlage, Resistenztestung

175. Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109(1):136-141.

176. Thijs JC, van Zwet AA, Thijs W J, Oey HB, Karrenbeld A, Stellaard F et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996; 91(10):2125-2129.

177. Laheij RJ, de Boer W A, Jansen JB, van Lier HJ, Sneeberger PM, Verbeek AL. Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard. J Clin Epidemiol 2000; 53(7):742-746.

178. Juttner S, Vieth M, Miehlke S, Schneider-Brachert W , Kirsch C, Pfeuffer T et al. Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in situ hybridization in formalin-fixed tissue. Mod Pathol 2004; 17(6):684-689.

179. Lottspeich C, Schwarzer A, Panthel K, Koletzko S, Russmann H. Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol 2007; 45(6):1718-1722.

180. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection --a critical review. Aliment Pharmacol Ther 2004; 20(10):1001-1017.

181. Leodolter A, Dominguez-Munoz JE, von Arnim U, Kahl S, Peitz U, Malfertheiner P. Validity of a modified 13C-urea breath test for pre-and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94(8):2100-2104.

182. Gisbert JP, de la MF, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101(8):1921-1930.

183. Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995; 14(5):428-433.

184. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91(6):1138-1144.

185. Bayerdorffer E, Oertel H, Lehn N, Kasper G, Mannes GA, Sauerbruch T et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989; 42(8):834-839.

186. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20(10):1161-1181.

187. Stolte M, Muller H, Talley NJ, O'Morain C, Bolling-Sternevald E, Sundin M et al. In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information. Pathol Res Pract 2006; 202(6):405-413.

188. Guidelines for clinical trials in Helicobacter pylori infection. W orking Party of the European Helicobacter pylori Study Group. Gut 1997; 41 Suppl 2:S1-S9.

189. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20(2):280-322.

190. Woo JS, El Zimaity HM, Genta RM, Yousfi MM, Graham DY. The best gastric site for obtaining a positive rapid ureas test. Helicobacter 1996; 1(4):256-259.

191. Tepes B. Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy. Scand J Gastroenterol 2007; 42(3):330-332.

192. van IJzendoorn MC, Laheij RJ, de Boer W A, Jansen JB. The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth J Med 2005; 63(4):141-145.

193. Leodolter A, Vaira D, Bazzoli F, Schutze K, Hirschl A, Megraud F et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18(9):927-931.

194. Hackelsberger A, Schultze V, Peitz U, Gunther T, Nilius M, Diete U et al. Performance of a rapid whole blood test for Helicobacter pylori in primary care: a German multicenter study. Helicobacter 1998; 3(3):179-183.

195. Peitz U, Baumann M, Tillenburg B, Borsch G, Stolte M, Malfertheiner P et al. [Insufficient validity of a rapid blood test for diagnosis of Helicobacter pylori infection]. Med Klin (Munich) 2001; 96(12):703-707.

196. Hoang TT, Rehnberg AS, Wheeldon TU, Bengtsson C, Phung DC, Befrits R et al. Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations. Clin Microbiol Infect 2006; 12(11):1112-1117.

197. Suerbaum S, Achtman M. Helicobacter pylori: recombination, population structure and human migrations. Int J Med Microbiol 2004; 294(2-3):133-139.

198. Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121(4):784-791.

236. Capurso G, Carnuccio A, Lahner E, Panzuto F, Baccini F, Delle FG et al. Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test results. Aliment Pharmacol Ther 2006; 24(10):1453-1460.

237. Kokkola A, Rautelin H, Puolakkainen P, Sipponen P, Farkkila M, Haapiainen R et al. Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand J Gastroenterol 2000; 35(2):138-141.

238. Korstanje A, van Eeden S, Offerhaus GJ, Sabbe LJ, den Hartog G, Biemond I et al. The 13carbon urea breath test for the diagnosis of Helicobacter pylori infection in subjects with atrophic gastritis: evaluation in a primary care setting. Aliment Pharmacol Ther 2006; 24(4):643-650.

239. Lahner E, Vaira D, Figura N, Pilozzi E, Pasquali A, Severi C et al. Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. Helicobacter 2004; 9(5):436-442.

240. Lehours P, Ruskone-Fourmestraux A, Lavergne A, Cantet F, Megraud F. W hich test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003; 98(2):291-295.

241. Schilling D, Jakobs R, Peitz U, Sulliga M, Stolte M, Riemann J et al. Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study. Digestion 2001; 63(1):8-13.

242. Laine LA, Nathwani RA, Naritoku W . The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later. Gastrointest Endosc 2005; 62(6):853-859.

243.Lee JM, Breslin NP, Fallon C, O'Morain CA. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000; 95(5):1166-1170.

244.Peitz U, Leodolter A, W ex T, Schutze D, Wolle K, Welte T et al. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol 2004; 42(2):141-146.

245.Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101(4):848-863.

246. Schilling D, Demel A, Adamek HE, Nusse T, W eidmann E, Riemann JF. A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis 2003; 35(4):217-221.

247. Brandi G, Biavati B, Calabrese C, Granata M, Nannetti A, Mattarelli P et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol 2006; 101(8):1756-1761.

248. Urita Y, Hike K, Torii N, Kikuchi Y, Kanda E, Kurakata H et al. Influence of urease activity in the intestinal tract on the results of 13C-urea breath test. J Gastroenterol Hepatol 2006; 21(4):744-747.

249. MacOni G, Vago L, Galletta G, Imbesi V, Sangaletti O, Parente F et al. Is routine histological evaluation an accurate test for Helicobacter pylori infection? Aliment Pharmacol Ther 1999; 13(3):327-331.

250. Stolte M, Wellens E, Bethke B, Ritter M, Eidt H. Helicobacter heilmannii (formerly Gastrospirillum hominis) gastritis: an infection transmitted by animals? Scand J Gastroenterol 1994; 29(12):1061-1064.

251. Chey W D, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997; 92(3):446-450.

252. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129(7):547-550.

253. Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99(5):823-829.

254. Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98(5):1005-1009.

255. Levine A, Shevah O, Shabat-Sehayek V, Aeed H, Boaz M, Moss SF et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004; 20(1):117-122.

256. Mana F, Van Laere W, Bossuyt A, Urbain D. The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test. Dig Liver Dis 2005; 37(1):28-32.

257. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N et al. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 2001; 15(1):73-79.

258. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56(6):772-781.

259. Stolte M, Stadelmann O, Bethke B, Burkard G. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995; 33(2):89-93.

260. Grimley CE, Holder RL, Loft DE, Morris A, Nwokolo CU. Helicobacter pylori-associated antibodies in patients with duodenal ulcer, gastric and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 1999; 11(5):503-509.

261. Han SR, Schneider T, Loos M, Bhakdi S, Maeurer MJ. One-step polymerase chain reaction-based typing of Helicobacter pylori vacA gene: association with gastric histopathology. Med Microbiol Immunol 1999; 188(3):131-138.

262. Lamarque D, Gilbert T, Roudot-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11(7):721-726.

263. Plummer M, van Doorn LJ, Franceschi S, Kleter B, Canzian F, Vivas J et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst 2007; 99(17):1328-1334.

264. Scholte GH, van Doorn LJ, Cats A, Bloemena E, Lindeman J, Quint WG et al. Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. Am J Gastroenterol 2002; 97(7):1687-1695.

265. Kodama K, Ito A, Nishizono A, Fujioka T, Nasu M, Yahiro K et al. Divergence of virulence factors of Helicobacter pylori among clinical isolates does not correlate with disease specificity. J Gastroenterol 1999; 34 Suppl 11:6-9.

266. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94(3):725-729.

267. Romano M, Marmo R, Cuomo A, De Simone T, Mucherino C, Iovene MR et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1(4):273-278.

268. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11(4):237-242.

269. Malfertheiner P, Peitz U, W olle K, Treiber G. [Helicobacter pylori infection--an update for 2004]. Dtsch Med W ochenschr 2004; 129(34-35):1821-1826.

270. Best LM, Haldane DJ, Keelan M, Taylor DE, Thomson AB, Loo V et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 2003; 47(10):3138-3144.

271. Grignon B, Tankovic J, Megraud F, Glupczynski Y, Husson MO, Conroy MC et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist 2002; 8(1):61-66.

272. Perna F, Gatta L, Figura N, Ricci C, Tampieri A, Holton J et al. Susceptibility of Helicobacter pylori to metronidazole. Am J Gastroenterol 2003; 98(10):2157-2161.

273. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;(2):CD003840.

274. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93(9):1409-1415.

275. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W , W illich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15(12):1949-1958.

276. Liu CC, Lee CL, Chan CC, Tu TC, Liao CC, Wu CH et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med 2003; 163(17):2020-2024.

323. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56(6):772-781.

324. Sharma VK, Sahai AV, Corder FA, Howden CW. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15(12):1939-1947.

325. Sonnenberg A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94(4):950-954.

326. Blum AL TNO. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339(26):1875-1881.

327. Froehlich F, Gonvers JJ, Wietlisbach V, Burnand B, Hildebrand P, Schneider C et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001; 96(8):2329-2336.

328. Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003; 18(2):245-252.

329. Koskenpato J. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. The American journal of gastroenterology 2001; 96(10):2866-2872.

330. Malfertheiner P. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Alimentary pharmacology & therapeutics 2003; 18(6):615-625.

331. McColl K. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. The New England journal of medicine 1998; 339(26):1869-1874.

332. McNamara D, Buckley M, Gilvarry J, O'Morain C. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. Helicobacter 2002; 7(5):317-321.

333. Talley NJ VN. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. The New England journal of medicine 1999; 341(15):1106-1111.

334. Veldhuyzen vZ, Fedorak RN, Lambert J, Cohen L, Vanjaka A. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98(9):1963-1969.

335. Hudson N, Brydon W G, Eastwood MA, Ferguson A, Palmer KR. Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment Pharmacol Ther 1995; 9(1):47-50.

336. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al. A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile-Associated Diarrhea with High Morbidity and Mortality. N Engl J Med 2005; 353(23):2442-2449.

337. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007; 13(5):761-763.

338. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease. JAMA 2005; 294(23):2989-2995.

339. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15(3):237-241.

340. Chiba N. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Alimentary pharmacology & therapeutics 2004; 19(3):349-358.

341. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129(5):1753-1755.

342. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(2):CD002096.

343. Vakil N. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Alimentary pharmacology & therapeutics 2006; 24(1):55-63.

344. Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 53(2):174-179.

345. Labenz J, Blum AL, BayerdOrffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112(5):1442-1447.

346. Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14(6):729-735.

347. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14(1):45-51.

348. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97(12):2992-2997.

349. Vakil N, Talley NJ, Stolte M, Sundin M, Junghard O, Bolling-Sternevald E. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in W estern patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006; 24(1):55-63.

350. Pilotto A, Perri F, Leandro G, Franceschi M. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology 2006; 52(2):99-106.

351. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53(1):12-20.

352. Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Veldhuyzen Van Zanten SJ, Burman CF et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease --results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16(8):1431-1442.

353. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121(5):1120-1126.

354. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46(5):615-621.

355. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117(2):319-326.

356. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60(2):237-246.

357. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis. World J Gastroenterol 2007; 13(40):5380-5383.

358. Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Umehara S et al. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol 2005; 84(12):807-811.

359. Suzuki T, Matsushima M, Masui A, W atanabe K, Takagi A, Ogawa Y et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005; 100(6):1265-1270.

360. Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97(3):812-814.

361. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110(12):3833-3841.

362. Yoshimura M, Hirai M, Tanaka N, Kasahara Y, Hosokawa O. Remission of severe anemia persisting for over 20 years after eradication of Helicobacter pylori in cases of Menetrier's disease and atrophic gastritis: Helicobacter pylori as a pathogenic factor in iron-deficiency anemia. Intern Med 2003; 42(10):971-977.

363. Kawasaki M, Hizawa K, Aoyagi K, Nakamura S, Fujishima M. Menetrier's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. Am J Gastroenterol 1997; 92(10):1909-1912.

364. Yamada M, Sumazaki R, Adachi H, Ahmed T, Matsubara T, Hori T et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156(3):182-185.

365. Bayerdorffer E, Ritter MM, Hatz R, Brooks W , Ruckdeschel G, Stolte M. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Menetrier's disease? Gut 1994; 35(5):701-704.

366. Madisch A, Miehlke S, Neuber F, Morgner A, Kuhlisch E, Rappel S et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23(4):473-479.

367. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis. World J Gastroenterol 2007; 13(40):5380-5383.

369. Choe YH, Kim SK, Son BK, Lee DH, Hong YC, Pai SH. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999; 4(2):135-139. IV. Pravention und Therapie neoplastischer Magenerkrankungen

370. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet, 1991, 338: 1175-1176.

371. Stolte M, Eidt S. Lymphoid follicles in the antral mucosa: immune response to Campylobacter pylori. J Clin Pathol 1989,42:1269-1271.

372. Stolte M. H. pylori and gastric MALT lymphoma. Lancet 1992,339:745-746.

373. Doglioni C, W otherspoon AC, Moschini A, de Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992,339:1175-1176.

374. Zaki M, Schubert ML. Helicobacter pylori and gastric lymphoma. Gastroenterology 1995,108:610-612.

375. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993,342:571-574.

376. Parsonnet J, Freidman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991,325:1127-1131.

377. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987,11:44-49.

378. Myhre MJ, Isaacson PG. Primary B-cell gastric lymphoma -a reassessment of its histogenesis. J Pathol 1987,152:1-11.

379. El-Zimaity HM, Wotherspoon A, de Jong D. Houston MALT lymphoma Workshop. Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus. Blood Cells Mol Dis. 2005;34:6-16.

380. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994;84:1361-1392.

381. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting -Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.

382. Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.

383. Musshoff K. Klinische Stadieneinteilung der nicht-Hodgkin-Lymphome. Strahlen-therapie 1977,153:218-222.

384. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated tissue: Factors relevant to prognosis. Gastroenterology 1992,102:1628-1638.

385. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999,131:88-95.

386. Shimodaira M, Tsukamoto Y, Niwa Y, et al. A proposed staging system for primary gastric lymphoma. Cancer 1994,73:2709-2715.

387. Ruskone-Fourmestraux A, Dragosics B, Morgner A, W otherspoon A, de Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut 2003,52:912-913.

388. Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007;13:3554-3566.

389. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.

390. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-1355.

391. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024.

392. Koch P, Probst A, Berdel W E, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23:7050-7059.

393. Koch P, del Valle F, Berdel W E, et al. German Multicenter Study Group. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001;19:3874-3883.

394. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000;119:1191-1202.

395. Raderer M, W ohrer S, Streubel B et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006;24:3136-3141.

396. Flieger D, Keller R, May A, Ell C, Fischbach W . Capsule endoscopy in gastrointestinal lymphomas. Endoscopy 2005;37:1174-1180.

397. Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001;19:2041-2048.

398. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005;97:1345-1353.

399. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001;19:4245-4251.

400. Boot H, de Jong D, van Heerde P, Taal B. Role of Helicobacter pylori eradication in high-grade MALT lymphoma. Lancet 1995;346:448-449

401. Morgner A, Bayerdorffer E, Neubauer A, Stolte M. Malignant tumours of the stomach: Gastric MALT lymphoma and Helicobacter pylori. In: Marshall B (ed): Gastroenterol Clin North Am 2000;29:593-607.

402. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.

403. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1996;124:275-276.

404. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-1355.

405. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999;131:88-95.

406. Savio A, Zamboni G, Capelli P, et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol's adequacy. Recent Results Cancer Res 2000;156:116-124.

407. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000;118: 821-828.

408. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001;48:297-303.

409. Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001;48:454-460.

410. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;Suppl 3:19-24.

411. Diz-Lois Palomares MT, Souto Ruzo J, Yanez Lopez JA, Alvarez Garcia A, Arnal Monreal F, Vazquez-Iglesias JL. Early-stage gastric MALT lymphomas: eradication of H. pylori and outcome. Rev Esp Enferm Dig 2002;94:669-678.

412. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-37.

413. Wundisch T, Thiede C, Morgner A, et al.Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024.

414. Wundisch T, Mosch C, Neubauer A, Stolte M. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series. Leuk Lymphoma 2006;47:2110-2114.

478. Sackmann M, Morgner A, Rudolph B, et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997;113:1087-1090.

479. Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Muller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002;360:547-548.

480. Thiede C, Wundisch T, Alpen B, et al. German MALT Lymphoma Study Group. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001:19:1600-1609.

481. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007;56:1685-1687.

482. Ott G, Katzenberger T, Greiner A, et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997;57:3944-3948.

483. Auer IA, Gascoyne RD, Connors JM, et al.:t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997; 8: 979-985.

484. Baens M, Maes B, Steyls A, Geboes K, Marynen P, De W olf-Peeters C. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000;156:1433-1439.

485. Liu H, Ruskone-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40.

486. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-1294.

487. Alpen B, Neubauer A, Dierlamm J, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000;95:4014-4015.

488. Nakamura T, Nakamura S, Yonezumi M, et al.: Helicobacter pylori and the t(11;18)(q21;q21) translocation in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J Cancer Res 2000;91:301-309.

489. Ye H, Dogan A, Karran L, et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol 2000;157:1147-1154.

490. Sugiyama T, Asaka M, Nakamura T, Nakamura S, Yonezumi N, Seto M: API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 2001,120:1884-1885.

491. Raderer M, Streubel B, W ohrer S, Hafner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006;55:616-618.

492. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000;46:1093-1103.

493. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-1921.

494. Tsang RW , Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164.

495. Tsang RW , Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005;23:10-17.

496. Mittal B, Wasserman TH, Griffith RC. Non-Hodgkin's lymphoma of the stomach. Am J Gastroenterol 1983;78:780-787.

497. Ettinger DS, Carter D. Gastric carcinoma 16 years after gastric lymphoma irradiation. Am J Gastroenterol 1977;68:485-488.

498. Shani A, Schutt AJ, W eiland LH. Primary gastric malignant lymphoma followed by gastric adenocarcinoma: report of 4 cases and review of the literature. Cancer 1978;42:2039-2044.

499. Bartlett DL, Karpeh MS Jr, Filippa DA, Brennan MF. Long-term follow-up after curative surgery for early gastric lymphoma. Ann Surg 1996;223:53-62.

500. Kodera Y, Yamamura Y, Nakamura S, et al. The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg 1998;227:45-50.

501. Brands F, Monig SP, Raab M. Treatment and prognosis of gastric lymphoma. Eur J Surg 1997;163:803-813.

502. Aviles A, Nambo MJ, Neri N, Huerta-Guzman J et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 2004;240:44-50.

503. Aviles A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005;22:57-62.

504. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.

505. Nakamura S, Matsumoto T, Suekane H, et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005;104:532-540.

506. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061-5066.

507. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877.

508. Streubel B, Ye H, Du MQ, Isaacson PG, Chott A, Raderer M. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004;66:476-480.

509. Raderer M, W ohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442-8446.

510. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.

511. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-310.

512. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.

513. Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab. Dig Dis Sci 2006;51:775-778.

514. Salar A, Bellosillo B, Serrano S, Besses C. Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. J Clin Oncol 2005;23:7361-7362.

515. Ferreri AJ, Freschi M, Dell'Oro S, Viale E, Villa E, Ponzoni M. Prognostic significance of the histopathologic recognition of low-and high-grade components in stage I-II B-cell gastric lymphomas. Am J Surg Pathol 2001;25:95-102.

516. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007;[Epub ahead of print].

517. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.

518. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.

519. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998;115:642-648.

520. Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Bergstrom R, Nyren O. Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma--a population-based study in Sweden. Br J Cancer 2000;83:391-396.

521. WHO/IARC. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-240.

522. Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 2004;341:1-17.

523. Ekstrom AM, Eriksson M, Hansson LE, et al. Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res 1999;59:5932-5937.

524. Miehlke S, Kirsch C, Agha-Amiri K, et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000;87:322-327.

541. Ekstrom AM, Serafini M, Nyren O, Hansson LE, Ye W, Wolk A. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 2000;87:133-140.

542. Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:345-354.

543. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000l;119:7-14.

544. De Jonge PJ, W olters LM, Steyerberg EW, van Dekken H, Kusters JG, Kuipers EJ, Siersema PD. Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in a Durch cohort. Aliment Pharmacol Ther 2007;26(1):31-39.

545. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer 2007;96(1):631-638.

546. Crew KD, Neugut AI. Epidemiology of gastric cancer. W orld J Gastroenterol 2006;12(3):354-362.

547. Meining A, Stolte M. Close correlation of intestinal metaplasia and corpus gastritis in patients infected with Helicobacter pylori. Z Gastroenterol 2002;40:557-560.

548. Matsuhisa T, Matsukura N, Yamada N. Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations: age-, gender-, and endoscopic diagnosis-matched study. J Gastroenterol 2004;39:324-328.

549. Imagawa S, Yoshihara M, Ito M, et al. Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled Cross-sectional Study. Dig Dis Sci 2007 13;[Epub ahead of print].

550. Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998;78:263-266.

551. Meining AG, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999;11:717-720.

552. Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol 2002;55:770-773.

553. Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch 2000;437:581-590 .

554. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.

555. Wong BC, Lam SK, Wong W M, et al.: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194.

556. Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of 'search and eradicate'. Aliment Pharmacol Ther 2004;19(Suppl1):17-21.

V. Therapie der Helicobacter pylori Infektion

557. Fischbach L., Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57.

558. Janssen MJ, Laheij RJ, et al. The influence of pretreatment on cure rates of Helicobacter pylori eradication. Neth J Med 2004;62:192-6.

559. Laheij RJ, Rossum LG, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection -a meta-analysis. Aliment Pharmacol Ther 1999;13(7) 857-64.

560. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.

561. van der W ouden EJ, Thijs JC, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a metaanalysis. Am J Gastroenterol 1999;94:1751-9.

562. Fuccio L, Minardi ME, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.

563. Furuta T, Shirai N, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005;20:153-67.

564. Gisbert JP, Khorrami S, et al. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617-29.

565. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000;118(Suppl 1):S2-8.

566. Huang JQ, Zheng GF, et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. W orld J Gastroenterol 2005;11:2726-32.

567. Klotz U, Schwab M, et al. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2-8.

568. Lind T, Megraud F, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116: 248-53.

569. Malfertheiner P, Bayerdorffer E, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-12.

570. Malfertheiner P, Peitz U, et al. W hat constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003;17 (Suppl B):53B-57B.

571. Malfertheiner P, Megraud F, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.

572. Moayyedi P, Soo S, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD002096.

573. Morgner A, Labenz J, et al. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016.

574. Padol S, Yuan Y, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006;101:1467-75.

575. Treiber G, Malfertheiner P, et al. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007;8:329-50.

576. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.

577. Hopkins RJ. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology 1997;113:S126-30.

578. Graham DY, Lu H, et al. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.

579. Calvet X, Garcia N, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14: 603-9.

580. Chiba N, Rao BV, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.

581. Gisbert JP, Khorrami S, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:757-66.

582. Graham DY, Hammoud F, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.

583. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999;13:719-29.

584. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996;91:246-57.

585. Treiber G. Treating H. pylori shorter than one week--a real future perspective? Z Gastroenterol 2000;38:807-12.

586. Unge P. Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies. Eur J Surg Suppl 1998;582:16-26.

587. Ford AC, Delaney BC, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.

588. Gene E, Calvet X, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003;17:1137-43.

589. Kist M. Helicobacter pylori: primary antimicrobial resistance and first-line treatment strategies. Euro Surveill 2007;12:E1-2.

590. Taylor JL, Zagari M, et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87-97.

591. Wolle K, Leodolter A, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;51:705-9.

592. Fischbach LA, van Zanten S, et al. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.

611. Neville PM, Everett S, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501.

612. Treiber G, W ittig J, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.

613. Vaira D, Zullo A, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.

614. Zullo A, De Francesco V, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.

615. Treiber G, Malfertheiner P, et al. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007;8:329-50.

616. Janssen MJ, Laheij RJ, et al. Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther 2005;21:341-5.

617. Klotz U, Schwab M, et al. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2-8.

618. de Bortoli N, Leonardi G, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007;102:951-6.

619. Gotteland M, Brunser O, et al. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-86.

620. Tong JL, Ran ZH, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25: 55-68.

621. Leodolter A, Kulig M, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-58.

622. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998;93: 1080-4.

623. Adamek RJ, Opferkuch W , et al. Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin. Am J Gastroenterol 1996:91:98-100.

624. van der W ouden EJ, Thijs JC, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.

625. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.

626. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.

627. Miehlke S, Schneider-Brachert W , Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008;13:69-74.

628. Yuan Y, Thabane L, et al. Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence? Aliment Pharmacol Ther 2006;23:1283-5; author reply 1285-6. VII.Nicht mit Helicobacter pylori assoziierte gastroduodenale Ulkuserkrankungen

796. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-130.

797. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-2099.

798. Hawkey CJ, W einstein WM, Smalley W, et al. Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology 2007;133:57-64.

799. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative metaanalysis. BMJ 1996;312:1563-1566.

800. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.

801. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-710.

802. Miyake K, Ueki N, Suzuki K, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther 2005;21 (Suppl 2):67-72.

803. Stupnicki T, Dietrich K, Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003;68:198-208.

804. Labenz J, Blum AL, Bolten WW , et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-335.

805. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-175.

806. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.

807. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528, 1522 p following 1528

808. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110.

809. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004;127:1038-1043.

810. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948.

811. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1308.

812. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-828, 828 e811-815; quiz 768.

813. Chan FK, Wong VW , Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet 2007;369:1621-1626.

814. Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007;5:1167-1174.

815. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.

816. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.

817. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.

818. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-1418.

819. Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of elicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther 2003;18:829-836.

820. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-1021.

821. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973.

822. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.

823. Kelly JP, Kaufman DW , Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-1416.

824. Slattery J, W arlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995;37:509-511.

825. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.

826. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-786.

827. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-2038.

828. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-244.

829. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006;4:860-865.

830. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006;333: 726.

831. Summers RW, Switz DM, Sessions JT, Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869.

832. Malchow H, Ewe K, Brandes JW , et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-266.

833. Guslandi M, Tittobello A. Symptomatic response to omeprazole in inflammatory bowel disease. J Clin Gastroenterol 1996;22:159-160.

834. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol 1994;18:317-319.

835. Cheung AN, Ng IO. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993;88:1882-1886.

836. Dorigo-Zetsma JW, van der Meer JT, Tersmette M, et al. Value of laboratory investigations in clinical suspicion of cytomegalovirus-induced upper gastrointestinal tract ulcerations in HIV-infected patients. J Med Virol 1996;49:29-33.

837. Peter A, Telkes G, Varga M, Sarvary E, Kovalszky I. Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 2004;18:580-584.

838. Pruitt BA, Jr., Foley FD, Moncrief JA. Curling's ulcer: a clinical-pathology study of 323 cases. Ann Surg 1970;172:523-539.

839. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377-381.

840. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. Jama 1996;275:308-314.

841. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-596.

842. Rosen HR, Vlahakes GJ, Rattner DW. Fulminant peptic ulcer disease in cardiac surgical patients: pathogenesis, prevention, and management. Crit Care Med 1992;20:354-359.

843. Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med 2007;2:86-9

СПИСОК ЛіТЕРАТУРи, використаної В ПРОЦЕСІ АДАПТАЦІЇ клінічної настанови
1.Бабак О.Я., Фадеенко Г.Д., Соломенцева Т.А.Резистентность Helicobacter pylori к антибактериальным препаратам //Клиническая антибиотикотерапия.-1999.-№2(2).-с.29-31.

2.Бабак О.Я., Фадеенко Г.Д. и соавт. Резистентность бактерий Helicobacter pylori к антибиотикам у больных с патологией желудка и двенадцатиперстной кишки//Инфекционные болезни в практике терапевта.-2001-с.26-28.

3. Харченко, Н.В. Международный конресс гастроэнтерологов «Гастро-2009»/Н.В.Харченко, Н.Д.Опанасюк, И.Я.Лопух // Здоров’я України. – 2009. - №23 (228). – с. 17-19.

4. Ткач С.М. Предпочтительные стратегии эрадикации инфекции Helicobacter pylori в Украине в свете современных международных рекомендаций//Новости медицины и фармации .-2013.-№468.-с.7-12.

5. Peter Malfertheiner, Francis Megraud, Colm A O’Morain, John Atherton, Anthony T R Axon, Franco Bazzoli, Gian Franco Gensini, Javier P Gisbert, David Y Graham, Theodore Rokkas, Emad M El-Omar, Ernst J Kuipers, The European Helicobacter Study Group (EHSG) Management of Helicobacter pylori infection the. Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-664.

6. Management of patients with ulcer bleeding. American College of Gastroenterology. NGC:009266 AHRQ (US) - Agency for Healthcare Research and Quality Mar 01, 2012